KRAS and cancer: The differential susceptibility between normal fibroblasts and cancer cell responses to AHE and AHE-2 in cell viabilities could be attributable to the differences in the genetic background, such as the oncogenic addition on Myc, KRAS, or MET oncogenes or tumor suppressor gene mutations in cancer cells.